Has Puneet Bhalla, MD received payments from drug or device companies?

Yes. Drug and device makers reported $127,163 in general payments to Puneet Bhalla, MD across 531 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Puneet Bhalla, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Puneet Bhalla, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Puneet Bhalla, MD

Medical Oncology · Chandler, AZNPI 1336115542

Payments from drug & device makers

$127,163in general payments, 2019–2025

Across 531 payments — averaging $239.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$118K
Bristol Myers Squibb$1K
AstraZeneca$665
Pfizer$629
E.r. Squibb & Sons, L.L.C.$528
Johnson & Johnson$519
plus $5K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	48	$118,255
Bristol Myers Squibb	80	$1,105
AstraZeneca(2 entities)	35	$665
Pfizer	37	$629
E.r. Squibb & Sons, L.L.C.	35	$528
Johnson & Johnson	35	$519
Merck	28	$410
Genentech USA, Inc.	14	$392
Novartis	18	$332
Exelixis Inc.	6	$294
Rigel Pharmaceuticals, Inc.	13	$288
Pharmacyclics LLC, An Abbvie Company	12	$250
Daiichi Sankyo Inc.	11	$243
Gilead(2 entities)	13	$239
Sanofi	11	$215
Eisai Inc.	10	$207
Regeneron Healthcare Solutions, Inc.	3	$194
Amgen	12	$187
GSK	9	$176
Puma Biotechnology, Inc.	8	$159
Karyopharm Therapeutics Inc.	5	$139
Mirati Therapeutics, Inc.	7	$132
Astellas Pharma US Inc	6	$116
Array Biopharma Inc	8	$95
Janssen Scientific Affairs, LLC	2	$84
Stemline Therapeutics Inc.	4	$76
Jazz Pharmaceuticals Inc.	3	$73
Intuitive Surgical	1	$69
Incyte Corporation	4	$68
AVEO Pharmaceuticals, Inc.	4	$67
Takeda Pharmaceuticals U.S.A., Inc.	3	$65
Ipsen Biopharmaceuticals, Inc	3	$62
Seagen Inc.	4	$60
Tersera Therapeutics LLC	2	$55
Beone Medicines USA, Inc.	2	$55
Bayer	3	$52
Beigene USA, Inc.	2	$45
EMD Serono, Inc.	2	$40
Clovis Oncology, Inc.	2	$37
Boehringer Ingelheim	2	$37
Geron Corporation	1	$33
Myovant Sciences Inc.	2	$31
Springworks Therapeutics, Inc.	1	$30
Viiv Healthcare Company	1	$29
Taiho Oncology, Inc.	2	$28
Epizyme, Inc.	1	$26
Recordati_rare_diseases_inc.	1	$25
Progenics Pharmaceuticals, Inc.	1	$24
CTI Biopharma Corp.	1	$20
Amneal Pharmaceuticals LLC	1	$20
Pharmacosmos Therapeutics Inc.	1	$19
Nestle Healthcare Nutrition Inc.	1	$19
Novocure Inc.	1	$17
Adaptive Biotechnologies Corporation	1	$17
Lexicon Pharmaceuticals, Inc.	1	$15
Pharmaessentia USA Corporation	1	$15
Teva Pharmaceuticals USA, Inc.	1	$15
Foundation Medicine, Inc.	1	$15
Chiesi USA, Inc.	1	$13
Blueprint Medicines Corporation	1	$13

How this compares

$127,163 in reported general payments places this provider in the 65th percentile of 59 medical oncology providers in Arizona.

See all medical oncology providers in Arizona →

Medicare billing

Part B allowed, 2024

$2,244,097

Medicare patients

587

Services billed

96,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Chandler

Michael BookmanTucson$4.8M
Erkut BorazanciScottsdale$3.5M
Daniel von HoffScottsdale$2.5M
Jason SalganickPhoenix$1.6M
Allan Espinosa MorazanPrescott$1.1M
Iyad HamarnehPrescott$855K
Isaac BowmanGilbert$844K
Saba RadhiGilbert$540K
Roopesh KantalaMesa$491K
Mital PatelPhoenix$484K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →